Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
laserskin
- Development stage
- Discontinued
- Lead developer
- Fidia Advanced Biopolymers
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
Laserskin is an autologous epidermal replacement (AER) developed by Fidia Advanced Biopolymers. It consists of a transparent, biodegradable, microperforated membrane scaffold made from HYAFF (a benzyl ester derivative of hyaluronic acid) seeded with preconfluent autologous keratinocytes isolated from a patient biopsy. Laserskin functions as a tissue-engineered skin graft (a biologic/cell-based therapy) and serves as the epidermal layer in the TissueTech Autograft System (TTAS), typically applied after the dermal substitute Hyalograft 3D. It is primarily indicated for the treatment of diabetic foot ulcers (DFUs) and other chronic wounds.
- Brand names
- LaserskinLaserskin Autograft
Beyond the preview
Go deeper on laserskin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on laserskin.